Precision Biosciences has appointed David Thompson to the new position of chief development officer. Thompson comes to Durham, NC-based Precision from Shire (NASDAQ: [[ticker:SHPG]]), where he was senior vice president and global head of research and nonclinical development. In his new role, Thompson will oversee Precision’s preclinical strategy for gene therapies and cell therapies based on the company’s genome editing technology.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
